BACK

Hematological > B-NHL

Clinical trial information


Select trial for more information

Area under investigation,AML/MDS,B-ALL,B-NHL=true,Classical Hodgkin lymphoma,CLL,DLBCL/LBCL,FL,MCL,Multiple myeloma

ALLight trial overview

Tumor

R/R B-Cell ALL

Trial Identifier

NCT07109219

Phase

I/II

Regimen

AZD4512 monotherapy and in combination with other anticancer treatments

Visit ct.gov
Go

DURGA-1 trial overview

Tumor

Relapsed/refractory multiple myeloma

Trial Identifier

NCT05850234

Phase

I/II

Regimen

AZD0120 (GC012F)

Visit ct.gov
Go

DURGA-2 trial overview

Tumor

Early line MM (including newly diagnosed MM and early relapsed or primary refractory MM)

Trial Identifier

NCT07073547

Phase

I

Regimen

AZD0120

Visit ct.gov
Go

DURGA-3 trial overview

Tumor

Relapsed/refractory MM

Trial Identifier

NCT06235229

Phase

I/II

Regimen

AZD0120

Visit ct.gov
Go

DURGA-4 trial overview

Tumor

Relapsed refractory multiple myeloma 

Trial Identifier

NCT07391657

Phase

III

Regimen

AZD0120; DKd, DPd, PVd or Kd (investigator’s choice) until PD or intolerable toxicity

Visit ct.gov
Go

ESCALADE trial overview

Tumor

Previously untreated non-GCB subtype DLBCL

Trial Identifier

NCT04529772

Phase

III

Regimen

R-CHOP ± acalabrutinib

Visit ct.gov
Go

Lumi-NHL trial overview

Tumor

R/R B-NHL

Trial Identifier

NCT07123454

Phase

I/II

Regimen

AZD4512 monotherapy or in combination with other anticancer treatments

Visit ct.gov
Go

MOMENTUM trial overview

Tumor

AML/MDS with KMT2Ar, NPM1m, or other genotypes associated with HOX overexpression

Trial Identifier

NCT07155226

Phase

I/II

Regimen

AZD3632 (module 1), AZD3632 + posaconazole (Module 2)

Visit ct.gov
Go

NCT04594642 trial overview

Tumor

R/R B-NHL

Trial Identifier

NCT04594642

Phase

I

Regimen

Surovatamig

Visit ct.gov
Go

NCT06106945 trial overview

Tumor

R/R multiple myeloma

Trial Identifier

NCT06106945

Phase

I/II

Regimen

Vemzatatug vedotin

Visit ct.gov
Go

PRIMAVERA trial overview

Tumor

R/R classical Hodgkin lymphoma

Trial Identifier

NCT06137144

Phase

I/II

Regimen

AZD3470 as monotherapy and in combination with anticancer agents

Visit ct.gov
Go

SOUNDTRACK-B trial overview

Tumor

Relapsed/refractory B-cell NHL or FL and LBCL

Trial Identifier

NCT06526793

Phase

II

Regimen

Surovatamig monotherapy

Visit ct.gov
Go

SOUNDTRACK-C1 trial overview

Tumor

CLL/SLL with uIGHV

Trial Identifier

NCT07509151

Phase

III

Regimen

Surovatamig consolidation therapy

Visit ct.gov
Go

SOUNDTRACK-D2 trial overview

Tumor

Newly diagnosed LBCL

Trial Identifier

NCT07215585

Phase

III

Regimen

Surovatamig; R-mini-CHOP

Visit ct.gov
Go

SOUNDTRACK-E trial overview

Tumor

R/R CLL/SLL, MCL, and LBCL

Trial Identifier

NCT06564038

Phase

I/II

Regimen

Sub-study 1 (RR CLL/SLL): surovatamig IV or SC; sub-study 2 (RR MCL): surovatamig IV or SC; sub-study 3 (RR LBCL): surovatamig IV + R-CHOP

Visit ct.gov
Go

SOUNDTRACK-F1 trial overview

Tumor

Previously untreated follicular lymphoma

Trial Identifier

NCT06549595

Phase

III

Regimen

Surovatamig + rituximab; SoC Immunochemotherapy

Visit ct.gov
Go

SYRUS trial overview

Tumor

Relapsed/refractory B-cell acute lymphoblastic leukemia

Trial Identifier

NCT06137118

Phase

I/II

Regimen

Surovatamig monotherapy

Visit ct.gov
Go

TITANium trial overview

Tumor

Relapsed/Refractory LBCL, FL, MCL, and CLL

Trial Identifier

NCT06542250

Phase

I/II

Regimen

AZD5492 monotherapy

Visit ct.gov
Go

Some compounds herein refer to selected AstraZeneca pipeline products still under development. AstraZeneca pipeline products are investigational products and, as such, are not approved by the US Food & Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory agency for the uses under investigation. Information regarding these investigational products should, under no circumstances, be regarded as a recommendation for their use or of their safety or efficacy.

This site is intended for US Healthcare Professionals.

Veeva ID: Z4-84958 US-109129 DE-92568 Last Updated October 20263/26
©2026 AstraZeneca. All rights reserved.